These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29027424)

  • 1. [Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease].
    Pan YT; Xu FY; Yu XZ; Shang WB
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1109-1112. PubMed ID: 29027424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effect of Fuzi Lizhong Decoction against Non-alcoholic Fatty Liver Disease via Anti-inflammatory Response through Regulating p53 and PPARG Signaling.
    Yang J; Ma W; Mei Q; Song J; Shu L; Zhang S; Li C; An L; Du N; Shi Z
    Biol Pharm Bull; 2020; 43(11):1626-1633. PubMed ID: 33132309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
    Zhou H; Ma C; Wang C; Gong L; Zhang Y; Li Y
    Eur J Pharmacol; 2021 May; 898():173976. PubMed ID: 33639194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.
    Chen H; Tan H; Wan J; Zeng Y; Wang J; Wang H; Lu X
    Pharmacol Ther; 2023 May; 245():108391. PubMed ID: 36963510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
    Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
    J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress.
    Gong P; Long H; Guo Y; Wang Z; Yao W; Wang J; Yang W; Li N; Xie J; Chen F
    J Ethnopharmacol; 2024 Jan; 318(Pt B):116927. PubMed ID: 37532073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.
    Awad AS; Abd Al Haleem EN; El-Bakly WM; Sherief MA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):381-91. PubMed ID: 26753695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.
    Liu Q; Zhu L; Cheng C; Hu YY; Feng Q
    Curr Pharm Des; 2017; 23(34):5136-5162. PubMed ID: 28925892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.
    Liu C; Liao JZ; Li PY
    World J Gastroenterol; 2017 Mar; 23(11):1964-1973. PubMed ID: 28373762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis on mechanisms and medication rules of herbal prescriptions for nonalcoholic fatty liver disease based on methods of data mining and biological information].
    Ding J; Zhang B; Wang PJ; He GN; Wei DM; Ding JL; Wang BC
    Zhongguo Zhong Yao Za Zhi; 2019 Apr; 44(8):1689-1695. PubMed ID: 31090336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
    Zhang X; Ji R; Sun H; Peng J; Ma X; Wang C; Fu Y; Bao L; Jin Y
    Free Radic Res; 2018 Feb; 52(2):198-211. PubMed ID: 29400110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
    Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
    Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
    Sun X; Zhang Y; Xie M
    Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
    Im AR; Kim YH; Lee HW; Song KH
    J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herbal medicines and nonalcoholic fatty liver disease.
    Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY
    World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.
    Zhou Z; Zhang J; You L; Wang T; Wang K; Wang L; Kong X; Gao Y; Sun X
    Front Endocrinol (Lausanne); 2022; 13():1000727. PubMed ID: 36204095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes.
    He W; Xu Y; Zhang C; Lu J; Li J; Xiang D; Yang J; Chang M; Liu D
    Drug Des Devel Ther; 2017; 11():3449-3460. PubMed ID: 29255346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.